News
J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.
The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...
Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its ...
Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.
Johnson & Johnson on Wednesday reported second quarter results that topped estimates and the company lifted its full-year outlook.
The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...
13hon MSN
The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of ...
Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results